Immunic Net Invested Capital from 2010 to 2024

IMUX Stock  USD 1.18  0.09  7.09%   
Immunic Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital will likely drop to about 27.5 M in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
28.9 M
Current Value
27.5 M
Quarterly Volatility
39.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic main balance sheet or income statement drivers, such as Depreciation And Amortization of 105.5 K, Interest Expense of 730.2 K or Other Operating Expenses of 54.8 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0095 or PTB Ratio of 1.34. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.
  
This module can also supplement Immunic's financial leverage analysis and stock options assessment as well as various Immunic Technical models . Check out the analysis of Immunic Correlation against competitors.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Latest Immunic's Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Immunic over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Immunic's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Pretty Stable
   Net Invested Capital   
       Timeline  

Immunic Net Invested Capital Regression Statistics

Arithmetic Mean61,809,430
Geometric Mean51,812,165
Coefficient Of Variation64.39
Mean Deviation28,554,095
Median50,044,000
Standard Deviation39,800,530
Sample Variance1584.1T
Range146.4M
R-Value0.26
Mean Square Error1590.9T
R-Squared0.07
Significance0.35
Slope2,311,190
Total Sum of Squares22177.2T

Immunic Net Invested Capital History

202427.5 M
202328.9 M
2022113.7 M
2021127.1 M
2020158.8 M
201958.4 M
201812.4 M

About Immunic Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunic income statement, its balance sheet, and the statement of cash flows. Immunic investors use historical funamental indicators, such as Immunic's Net Invested Capital, to determine how well the company is positioned to perform in the future. Although Immunic investors may use each financial statement separately, they are all related. The changes in Immunic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunic Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital28.9 M27.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Immunic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunic Stock:
Check out the analysis of Immunic Correlation against competitors.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Immunic Stock analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stocks Directory
Find actively traded stocks across global markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Commodity Directory
Find actively traded commodities issued by global exchanges
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.11)
Return On Assets
(0.68)
Return On Equity
(1.31)
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.